Concepedia

Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer

Robert J. van Soest, Ellen S. de Morrée, Charlotte F. Kweldam, Corrina M.A. de Ridder, Erik A.C. Wiemer, Ron H.J. Mathijssen, Ronald de Wit, Wytske M. van Weerden

European Urology · 2014 · 130 citations · 8 references

DOI

Concepts

References

8

Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

Tomasz M. Beer, Andrew J. Armstrong, Dana E. Rathkopf et al. · New England Journal of Medicine · 2014 · 3K citations · Full text

, , +17

Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy

Charles J. Ryan, Matthew R. Smith, Johann S. de Bono et al. · New England Journal of Medicine · 2012 · 2.8K citations · Full text

, , +17

Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?

Janusz Mezynski, Carmel Pezaro, Diletta Bianchini et al. · Annals of Oncology · 2012 · 248 citations

, , +16

Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer

Robert J. van Soest, Martin E. van Royen, Ellen S. de Morrée et al. · European Journal of Cancer · 2013 · 205 citations

, , +16

Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies

Nader Al Nakouzi, Sylvestre Le Moulec, Laurence Albigès et al. · European Urology · 2014 · 165 citations

, , +9